{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 132,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/30",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.15,
        "y": 0.38
      },
      "kind": "list",
      "text": "Neuroscience: ALKS 1140 (Complete phase 1 enabling activities, Initiate phase 1 first-in-human study, Initiate phase 0 biomarker study), Orexin (Nominate orexin candidate to the clinic)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a470fcb-735c-4982-b156-d71da23d2869",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "Oncology: IL-12 (Lead candidate generation), IL-18 (Advance lead candidate identification)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "669093c1-6831-45f1-99a0-9249dc22999c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.268
      },
      "kind": "title",
      "text": "Develop next generation of pipeline candidates",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db6f10eb-358d-4404-a9f4-cd14926d9e25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Disciplined Capital Allocation Supports Highest-ROI Priorities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4991e5e1-a20d-4c7d-8d6f-1a17410cba13",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "capital-allocation-framework",
      "slug": null,
      "matchId": "99ce55e3-4fe0-4ffa-ba16-697d642cffc4",
      "evidence": "Title explicitly mentions disciplined capital allocation supporting priorities.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}